Japan To Lower Price Caps On Key Prescription Drugs
This article was originally published in PharmAsia News
Executive Summary
Japan plans new price caps on prescription drugs in April, lowered by an average of 5.2 percent. Some of the most popular drugs produced by major drug makers face an even steeper reduction in the maximum price allowed, by 10.1 percent. The new caps are expected to cause more pharmaceutical makers to shift their focus from marketing drugs in Japan to other countries. Among drugs facing the greatest price reduction are those in a new generation of medicines to lower blood pressure, including Takeda's Blopress (candesartan cilexetil), Astellas' Micardis (telmisartan) and Daiichi Sankyo's Olmetec (olmesartan). (Click here for more - a subscription may be required